Seizert Capital Partners LLC Acquires 26,033 Shares of Elevance Health, Inc. (NYSE:ELV)

Seizert Capital Partners LLC raised its position in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 25.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 130,262 shares of the company's stock after purchasing an additional 26,033 shares during the period. Elevance Health makes up approximately 2.2% of Seizert Capital Partners LLC's holdings, making the stock its 17th largest holding. Seizert Capital Partners LLC owned approximately 0.06% of Elevance Health worth $48,054,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its stake in shares of Elevance Health by 26.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,523 shares of the company's stock valued at $792,000 after acquiring an additional 317 shares during the last quarter. Van ECK Associates Corp lifted its position in Elevance Health by 4.1% in the third quarter. Van ECK Associates Corp now owns 12,782 shares of the company's stock valued at $6,647,000 after purchasing an additional 507 shares during the last quarter. Intact Investment Management Inc. purchased a new stake in shares of Elevance Health during the third quarter valued at approximately $915,000. Impax Asset Management Group plc grew its holdings in shares of Elevance Health by 6.0% in the third quarter. Impax Asset Management Group plc now owns 25,305 shares of the company's stock worth $13,159,000 after purchasing an additional 1,435 shares during the last quarter. Finally, FSM Wealth Advisors LLC increased its stake in shares of Elevance Health by 6.5% in the third quarter. FSM Wealth Advisors LLC now owns 605 shares of the company's stock worth $315,000 after buying an additional 37 shares during the period. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Stock Up 1.6 %

ELV stock traded up $6.36 during trading on Thursday, hitting $403.83. 1,381,558 shares of the stock traded hands, compared to its average volume of 1,604,522. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The stock has a market cap of $91.81 billion, a price-to-earnings ratio of 15.77, a price-to-earnings-growth ratio of 1.18 and a beta of 0.83. Elevance Health, Inc. has a 1 year low of $362.21 and a 1 year high of $567.26. The firm's 50 day moving average is $389.26 and its two-hundred day moving average is $436.03.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. On average, sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Monday, March 10th will be given a dividend of $1.71 per share. The ex-dividend date of this dividend is Monday, March 10th. This is a boost from Elevance Health's previous quarterly dividend of $1.63. This represents a $6.84 annualized dividend and a dividend yield of 1.69%. Elevance Health's dividend payout ratio (DPR) is 26.71%.

Insider Buying and Selling

In other Elevance Health news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of Elevance Health stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $396.30, for a total value of $1,388,635.20. Following the completion of the sale, the executive vice president now owns 10,116 shares of the company's stock, valued at approximately $4,008,970.80. The trade was a 25.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.35% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ELV shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $485.00 price target on shares of Elevance Health in a report on Friday, January 24th. Stephens cut Elevance Health from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $520.00 to $440.00 in a report on Wednesday, January 22nd. Argus reissued a "hold" rating and set a $405.40 target price on shares of Elevance Health in a research note on Wednesday, January 29th. Wells Fargo & Company dropped their price target on Elevance Health from $483.00 to $478.00 and set an "overweight" rating for the company in a research note on Tuesday, January 28th. Finally, Barclays upped their price objective on shares of Elevance Health from $501.00 to $512.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Elevance Health has an average rating of "Moderate Buy" and a consensus price target of $517.03.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.